Lead Product(s) : CNP-104
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
COUR Receives Orphan Designation for CNP-104 in Primary Biliary Cholangitis
Details : CNP-104 is a biodegradable nanoparticle encapsulating the E2 component of the mitochondrial pyruvate dehydrogenase complex (PDC), a key autoantigen in PBC.
Product Name : CNP-104
Product Type : Enzyme
Upfront Cash : Inapplicable
January 08, 2025
Lead Product(s) : CNP-104
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RTX001
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I/ Phase II
Sponsor : Syncona
Deal Size : $83.0 million
Deal Type : Series B Financing
Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment
Details : The proceeds will be used to advance Resolution's lead candidate, RTX001, an autologous, engineered, pro-regenerative macrophage cell therapy for the treatment of end-stage liver disease.
Product Name : RTX001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 02, 2024
Lead Product(s) : RTX001
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I/ Phase II
Sponsor : Syncona
Deal Size : $83.0 million
Deal Type : Series B Financing
Lead Product(s) : CNP-104
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
COUR Pharmaceuticals Reports Positive Results from Phase 2a Study of CNP-104
Details : CNP-104 is a biodegradable nanoparticle encapsulating the E2 component of the mitochondrial pyruvate dehydrogenase complex. It is being evaluated for primary biliary cholangitis.
Product Name : CNP-104
Product Type : Peptide
Upfront Cash : Not Applicable
September 30, 2024
Lead Product(s) : CNP-104
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I/ Phase II
Sponsor : Hillstream BioPharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through the agreement, Hillstream aims to acquire a clinical stage asset, AV104 (nalmefene), an opioid antagonist, but first it intends to seek approval in an orphan disease for the treatment of moderate to severe cholestatic pruritis with primary biliar...
Product Name : AV104
Product Type : Small molecule
Upfront Cash : Undisclosed
September 11, 2023
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I/ Phase II
Sponsor : Hillstream BioPharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : GB1211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GB1211 demonstrated improvement and consistent signs of activity across biochemical liver function markers and markers of target engagement, apoptosis, and fibrosis, including reductions in galectin-3 (p<0.05) and CK-18 (M65) (p<0.002).
Product Name : GB1211
Product Type : Small molecule
Upfront Cash : Not Applicable
November 08, 2022
Lead Product(s) : GB1211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : GB1211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GB1211 is an orally available and potent small molecule galectin-3 inhibitor. Galecto’s initial target indications for GB1211 are liver cirrhosis, a severe, progressive disease that ultimately leads to liver failure, and non-small cell lung cancer.
Product Name : GB1211
Product Type : Small molecule
Upfront Cash : Not Applicable
October 17, 2022
Lead Product(s) : GB1211
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nanoparticle Encapsulating PDC-E2
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CNP-104 uses COUR's proprietary nanoparticle platform (CNP), a novel system which combines disease specific pathogenic antigens with state-of-the-art pharmaceutical nanoparticles that mimic normal removal of dead or dying liver cells from the body.
Product Name : CNP-104
Product Type : Large molecule
Upfront Cash : Not Applicable
January 10, 2022
Lead Product(s) : Nanoparticle Encapsulating PDC-E2
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Nanoparticle Encapsulating PDC-E2
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I/ Phase II
Sponsor : Ironwood Pharmaceuticals
Deal Size : $495.0 million
Deal Type : Acquisition